Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01040156
Recruitment Status : Completed
First Posted : December 29, 2009
Last Update Posted : December 29, 2009
Information provided by:
University Children’s Hospital Tuebingen

Brief Summary:
Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.

Condition or disease
Systemic Aspergillosis Systemic Candidiasis

Study Type : Observational
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Safety, Feasibility and Efficacy of Caspofungin Versus Liposomal Amphotericin B as Antifungal Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients - a Retrospective Phase I/II Study
Study Start Date : August 2008
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Pediatric patients undergoing allogeneic stem cell transplantation

Inclusion Criteria:

  • Pediatric patients under the age of 18 years
  • Pediatric patients after HSCT treated with caspofungin
  • Pediatric patients after HSCT treated with liposomal amphotericin

Exclusion Criteria:

  • Pediatric patients with uncontrolled hematological malignancies
  • Pediatric patients with IFI at start of HSCT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01040156

University Children's Hospital
Tuebingen, Germany, 72076
Sponsors and Collaborators
University Children’s Hospital Tuebingen
Principal Investigator: Ingo Mueller, M.D. UCHT Identifier: NCT01040156     History of Changes
Other Study ID Numbers: UCHT-1209
First Posted: December 29, 2009    Key Record Dates
Last Update Posted: December 29, 2009
Last Verified: December 2009

Additional relevant MeSH terms:
Lung Diseases, Fungal
Skin Diseases, Infectious
Skin Diseases
Liposomal amphotericin B
Antifungal Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents